Yaygın evre küçük hücreli akciğer kanserinde lenfosit/C-reaktif protein oranının prognostik önemi

Abstract

Amaç: Yaygın evre küçük hücreli akciğer kanseri (KHAK) hastalarında inflamatuar faktörlerden lenfosit/C-Reaktif protein oranının (LCR) tedavi öncesi prognostik önemini araştırmayı amaçladık. Araçlar ve Yöntem: Retrospektif olarak 2010-2020 tarihleri arasında KHAK tanısı almış ve yaygın evrede olan 514 hastanın tıbbi kayıtları incelendi. Kemoterapi öncesi alınan kan tetkiklerinden LCR hesaplandı. Bulgular: Yaygın evre KHAK’nin ortalama sağkalım süresi 6 aydır (5,3-6,7). Sınırlı ve yaygın hastalık arasında medyan genel sağkalım (OS) açısından istatistiksel anlamlı farklılık vardır (p<0.001). Hastaların başlangıç LCR değeri 0,5 (0-311) olarak saptandı. LCR’nin genel sağkalım üzerinde istatistiksel anlamlı etkisi vardır (0,025). LCR’deki 1 birimlik artış ölümü 1,004 kat azaltmaktadır Sonuç: Tedavi öncesi LCR, yaygın evre KHAK’de ortalama sağkalımı gösteren bağımsız bir prognostik parametre olarak kullanılabilir.

Keywords

• küçük hücreli akciğer kanseri
• lenfosit/CRP oranı
• prognostik faktör
• sağkalım

A noteworthy prognostic marker in extensive small cell lung cancer: lymphocyte/C-reactive protein ratio

Abstract

Aims: We aimed to investigate the pre-treatment prognostic significance of lymphocyte/C-Reactive protein ratio (LCR), one of the inflammatory factors, in patients with extensive-stage small cell lung cancer (SCLC). Methods: Medical records of 514 patients who were diagnosed with extensive-stage SCLC between 2010 and 2020 were examined retrospectively. LCR was calculated using the blood test results prior to chemotherapy. Results: The mean survival time for extensive-stage SCLC is 6 months (5.3-6.7). A statistically significant difference exists between limited and extensive stages in terms of median overall survival (OS) (p<0.001). The baseline LCR value of the patients was determined as 0.5 (0-311). LCR exerts a statistically significant effect on overall survival (0.025). Every 1 unit increase in LCR reduces death by 1.004 times. Conclusion: Pre-treatment LCR value can be used as an independent prognostic parameter associated with mean survival in extensive SCLC.

Keywords

• small cell lung cancer
• lymphocyte/CRP ratio
• prognostic factor
• survival

References

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539-4544.
2. Bernhardt EB, Jalal SI. Small cell lung cancer. Cancer Treat Res. 2016;170:301-322.
3. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987;39(2):146-149.
4. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27-41.
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454(7203):436-444.
6. Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of systemic immune‑inflammation index in cancer: a meta‑analysis. J Cancer. 2018;9:3295‑3302.
7. Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158-2167.
8. Li S, Yang Z, Du H, Zhang W, Che G, Liu L. Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score-matching study. ANZ J Surg. 2019;89(11):E507-E513.

9. Öztürk Ergür F, Öztürk A. A new prognostic marker in small cell lung cancer: red cell distribution width ratio of hemoglobin. Anatolian Curr Med J. 2023; 5(2); 148-152.
10. Bozkaya Y, Kurt B, Gürler F. A prognostic parameter in advanced non‑small cell lung cancer: the ratio of hemoglobin‑to‑red cell distribution width. Int J Clin Oncol. 2019;24:798‑806.
11. He Y, Gong R, Peng KW, Liu LZ, Sun LY, Wang HY. Lymphocyte-to-C-reactive protein ratio is a potential new prognostic biomarker for patients with lung cancer. Biomark Med. 2020;14(9):717-726.
12. Yılmaz H, Yersal Ö. Prognostic significance of novel inflammatory markers in extensive-stage small-cell lung cancer. J Can Res Ther. 2022;18:691-696.
13. İriağaç Y, Çavdar E, Yolcu A. The prognostic importance of lymphocyte/monocyte ratio in diffuse stage small cell lung cancer. Ahi Evran Med J. 2022; 6 (1):71-76.
14. Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):138-155.